ICCC Immucell (ICCC) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · In vitro & in vivo diagnostic substances · CIK 0000811641
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter
What the filings say about ICCC
Insiders, 180 days
+$76.0K net bought
1 buyer
Immucell insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, IMMUCELL CORP /DE/ insiders bought a net $76.0K of stock across 10 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Dec 4, 2025.
- +24.0% median (+25.6% mean) 90-day return after 3 previous buys.
- The trade is 45.0% of the 17,785 shares held after it.
- No other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO te Boekhorst Paul Francis Olivier bought about $76.0K of ICCC on Jun 18, 2026, the largest insider purchase at the company on our record; 13 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Dec 3, 2025.
- +26.4% median (+26.4% mean) 90-day return after 2 previous buys.
- The trade is 25.0% of the 9,738 shares held after it.
- 1 other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO te Boekhorst Paul Francis Olivier bought about $13.4K of ICCC on Dec 4, 2025; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 2, 2025.
- The trade is 49.2% of the 7,306 shares held after it.
- 1 other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO te Boekhorst Paul Francis Olivier bought about $18.2K of ICCC on Dec 3, 2025, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 2, 2025.
- The trade is 40.8% of the 6,264 shares held after it.
- 1 other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO te Boekhorst Paul Francis Olivier bought about $12.8K of ICCC on Dec 3, 2025; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 2, 2025.
- The trade is 36.0% of the 9,785 shares held after it.
- 1 other insider bought within 30 days.
- 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO te Boekhorst Paul Francis Olivier bought about $17.7K of ICCC on Dec 3, 2025; 1 other insider bought within 30 days and 13 funds added in the latest 13F quarter.10 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$76.0K over 180 days
more than 75% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
+4.3% year over year
more than 51% of Pharma & Biotech
Margin
-3.8% net margin
more than 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.4% of the float short (float per yahoo 2026-10-26) · 1.8 days to cover · settled 2026-09-30
below 85% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch ICCC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+69.0%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ICCC: institutional holders (13F)
13F holdings, latest reported quarter
268,130 sh
$2.7M
233,910 sh
$2.4M
171,089 sh
$1.7M
135,267 sh
$1.4M
72,270 sh
$726.5K
Congress trades in ICCC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ICCC planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
ICCC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Nationwide Bailard Small Cap Value Fund
$113.2K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$212.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$14.0K position · as of 2026-06-30
0.0%
LVIP Dimensional U.S. Core Equity 2 Fund
$14.3K position · as of 2026-06-30
0.0%
U.S. Social Core Equity 2 Portfolio
$23.6K position · as of 2026-07-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$793.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $76.0K bought by insiders over 180 days, 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
ICCC financials
Revenue growth
+4.3%
XBRL, annual
Net margin
-3.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$30.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ICCC
| FY Dec 2025 | $27.6M |
| FY Dec 2024 | $26.5M |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $18.6M |
| FY Dec 2021 | $19.2M |
| Jun 2026 | $7.2M |
| Mar 2026 | $10.4M |
| Dec 2025 | $7.6M |
| Sep 2025 | $5.5M |
| Jun 2025 | $6.4M |
| Mar 2025 | $8.1M |
| Dec 2024 | $7.8M |
| Sep 2024 | $6.0M |
At each fiscal year end
Single quarter
Net margin, TTM
+2.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ICCC
| FY Dec 2025 | -3.8% |
| FY Dec 2024 | -8.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -13.4% |
| FY Dec 2021 | -0.4% |
| Jun 2026 | +25.5% |
| Mar 2026 | +18.7% |
| Dec 2025 | -37.4% |
| Sep 2025 | -2.5% |
| Jun 2025 | +7.8% |
| Mar 2025 | +17.9% |
| Dec 2024 | +6.6% |
| Sep 2024 | -11.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ICCC
| FY Dec 2025 | $1.2M |
| FY Dec 2024 | -$107.8K |
| FY Dec 2023 | -$6.6M |
| FY Dec 2022 | -$5.5M |
| FY Dec 2021 | -$1.7M |
| Jun 2026 | $2.3M |
| Mar 2026 | $3.4M |
| Dec 2025 | $310.2K |
| Sep 2025 | -$1.8M |
| Jun 2025 | $1.4M |
| Mar 2025 | $1.2M |
| Dec 2024 | -$199.3K |
| Sep 2024 | -$727.7K |
At each fiscal year end
Single quarter
Debt to equity
0.26x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ICCC
| FY Dec 2025 | 0.34x |
| FY Dec 2024 | 0.38x |
| FY Dec 2023 | 0.84x |
| FY Dec 2022 | 0.63x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | 0.26x |
| Mar 2026 | 0.30x |
| Dec 2025 | 0.34x |
| Sep 2025 | 0.32x |
| Jun 2025 | 0.33x |
| Mar 2025 | 0.35x |
| Dec 2024 | 0.38x |
| Sep 2024 | 0.73x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.71x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ICCC
| FY Dec 2025 | 0.27x |
| FY Dec 2024 | 0.03x |
| FY Dec 2023 | -0.22x |
| FY Dec 2022 | -0.08x |
| FY Dec 2021 | 1.17x |
| Jun 2026 | 0.71x |
| Mar 2026 | 0.51x |
| Dec 2025 | 0.27x |
| Sep 2025 | 0.21x |
| Jun 2025 | 0.26x |
| Mar 2025 | 0.15x |
| Dec 2024 | 0.03x |
| Sep 2024 | -0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+2.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ICCC
| FY Dec 2025 | -3.8% |
| FY Dec 2024 | -8.2% |
| FY Dec 2023 | -20.9% |
| FY Dec 2022 | -7.9% |
| FY Dec 2021 | -0.3% |
| Jun 2026 | +2.6% |
| Mar 2026 | -1.9% |
| Dec 2025 | -3.8% |
| Sep 2025 | +8.3% |
| Jun 2025 | +6.6% |
| Mar 2025 | -1.0% |
| Dec 2024 | -8.2% |
| Sep 2024 | -14.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ICCC
| FY Dec 2025 | -2.4% |
| FY Dec 2024 | -4.9% |
| FY Dec 2023 | -13.0% |
| FY Dec 2022 | -5.6% |
| FY Dec 2021 | -0.2% |
| Jun 2026 | +1.8% |
| Mar 2026 | -1.2% |
| Dec 2025 | -2.4% |
| Sep 2025 | +5.2% |
| Jun 2025 | +4.2% |
| Mar 2025 | -0.6% |
| Dec 2024 | -4.9% |
| Sep 2024 | -8.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.9%
operating income after a 7.8% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ICCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +11.9% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | +6.9% |
| Jun 2025 | +5.1% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+9.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ICCC
| FY Dec 2025 | +4.2% |
| FY Dec 2024 | -4.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -5.5% |
| FY Dec 2021 | +0.6% |
| Jun 2026 | +9.6% |
| Mar 2026 | +6.1% |
| Dec 2025 | +4.2% |
| Sep 2025 | +5.7% |
| Jun 2025 | +4.6% |
| Mar 2025 | -0.6% |
| Dec 2024 | -4.1% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
146.29x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ICCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 143.57x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | 22.32x |
| Jun 2025 | 33.14x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$92.4M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ICCC
| FY Dec 2025 | $60.9M |
| FY Dec 2024 | $52.7M |
| FY Dec 2023 | $59.4M |
| FY Dec 2022 | $60.6M |
| FY Dec 2021 | $52.6M |
| Jun 2026 | $90.4M |
| Mar 2026 | $59.2M |
| Dec 2025 | $60.9M |
| Sep 2025 | $62.1M |
| Jun 2025 | $68.9M |
| Mar 2025 | $49.5M |
| Dec 2024 | $52.7M |
| Sep 2024 | $46.4M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+4.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield ICCC
| FY Dec 2025 | +2.2% |
| FY Dec 2024 | -0.2% |
| FY Dec 2023 | -16.6% |
| FY Dec 2022 | -11.7% |
| FY Dec 2021 | -2.7% |
| Jun 2026 | +4.6% |
| Mar 2026 | +5.9% |
| Dec 2025 | +2.2% |
| Sep 2025 | +1.3% |
| Jun 2025 | +2.8% |
| Mar 2025 | +1.8% |
| Dec 2024 | -0.2% |
| Sep 2024 | -2.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -67%, PEG needs growth
PEG, trailing ICCC
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $27.6M | $26.5M | $17.5M | $18.6M |
| Gross profit | $11.4M | $7.9M | $3.9M | $7.6M |
| Operating income | $1.6M | -$1.6M | -$5.7M | -$2.3M |
| Net income | -$1.0M | -$2.2M | -$5.8M | -$2.5M |
| EPS (diluted) | -0.12 | -0.26 | -0.75 | -0.32 |
| Operating cash flow | $2.5M | $357.9K | -$4.7M | -$1.5M |
| Cash | $3.8M | $3.8M | $978.7K | $5.8M |
| Long-term debt | $7.5M | $9.0M | $10.5M | $10.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
ICCC Stock Sonar score 6/7 axes
Find similar shapesCompareICCC ranks highest on profitability (74th percentile) and financial health (65th), and lowest on institutional and government (23rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ICCC filings, in plain words
Are Immucell insiders buying or selling ICCC?
In the 180 days to 2026-10-28, Immucell insiders were net buyers, a net $76.0K across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Immucell insiders were net buyers of ICCC, a net $76.0K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
